Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
207 stopped studies mapped to Malignant Cervical Neoplasm and descendants · 84% state a reason
Over the 207 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03108495 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients… | Phase 2 | terminated | Apr 11, 2017 | Iovance Biotherapeutics, Inc. | After reviewing available safety and efficacy data to date, Iovance concluded the study reached the… | Safety / toxicity |
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA… | Phase 1 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT05458960 | Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate(BASICS) | N/A | terminated | Jul 14, 2022 | Washington University School of Medicine | Staffing issues | Other (stated, no rule matched) |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Nov 29, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in… | Phase 2 | terminated | Jul 23, 2021 | Sun Yat-Sen University Cancer Center | No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding… | Enrollment / accrual |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer… | Phase 1 / Phase 2 | terminated | Dec 24, 2018 | Seagen, a wholly owned subsidiary of Pfizer | Sponsor has decided to stop the trial based on strategic decisions | Sponsor / business decision |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in… | Phase 2 | terminated | Mar 28, 2019 | Agenus Inc. | Sponsor strategic decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04016142 | Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced…(ACCRAPAN) | Phase 2 | terminated | Jul 11, 2019 | Centre Oscar Lambret | The study is discontinued because of recruitment failure, and for strategic reason (competitive… | Enrollment / accrual |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 3, 2020 | Sun Yat-sen University | Five patients were enrolled in the study, but no treatment response was observed and all the… | Efficacy / futility |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular… | N/A | withdrawn | Oct 7, 2025 | Timser SAPI de CV | The study did not start, i.e., no participants were enrolled, because the Mexican Regulatory… | Enrollment / accrual |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | N/A | withdrawn | May 9, 2023 | University of Oklahoma | Study withdrawn due to lack of accrual. | Enrollment / accrual |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 13, 2024 | Pheon Therapeutics | The study was terminated by Sponsor for strategic reasons. | Sponsor / business decision |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | Phase 1 / Phase 2 | terminated | May 2, 2022 | TCRCure Biopharma Ltd. | Study terminated due to strategic portfolio decision to reallocate resources to higher-priority… | Sponsor / business decision |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT04000477 | Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening…(ENDOCOL) | N/A | terminated | Jun 27, 2019 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent… | Phase 2 / Phase 3 | withdrawn | Mar 10, 2025 | Women's Hospital School Of Medicine Zhejiang University | no participants enrolled | Enrollment / accrual |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02554565 | Innovation for Standard Identification of Insertional HPV Mutations and of Target…(PAIR HPV) | N/A | terminated | Sep 18, 2015 | Institut Curie | Study in competition with another so it was decided to stop recruitment | Enrollment / accrual |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | Phase 3 | withdrawn | May 18, 2015 | National Institute of Cancerología | Due to a lack of sufficient resources, the opening was not carried out. | Other (stated, no rule matched) |
| NCT03255252 | Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer…(IMMUVIX) | Phase 2 | terminated | Aug 21, 2017 | Institut du Cancer de Montpellier - Val d'Aurelle | insufficient recruitment | Enrollment / accrual |
| NCT05462249 | Impact of Catch-up HPV Vaccination(HPVAC2) | — | terminated | Jul 18, 2022 | University Hospital, Brest | overestimation of the number of healthcare professionals participating in the inclusions | Other (stated, no rule matched) |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Phase 2 | terminated | Jul 23, 2020 | Baptist Health South Florida | Poor accrual related to change in standard of care treatment for this population. | Enrollment / accrual |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04278326 | Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments(ORGANOIDES) | N/A | terminated | Feb 20, 2020 | Centre Hospitalier Régional d'Orléans | the partner laboratory encountered various difficulties (COVID, relocation of the laboratory,… | COVID-19 / pandemic |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102… | Phase 3 | terminated | Jan 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor develops strategy adjustment | Sponsor / business decision |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the… | Phase 2 | terminated | May 17, 2018 | Brown University | Slow enrollment | Enrollment / accrual |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women… | — | withdrawn | Jul 22, 2022 | MetroHealth Medical Center | Personnel departure. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials